Abstract
Rationale: Chronic obstructive disease (COPD) is one of the most common respiratory diseases caused by exogenous noxae. Multiple comorbidities are characteristic of this chronic systemic disease. The FDA-approved biomarker for predicting disease prognosis competes with other (not approved) biomarkers such as proadrenomedullin and copeptin.
Methods: We compared sensitivity and specificity of these biomarkers using the data from the German COSYCONET (COPD and Systemic Consequences - Comorbidities Network) cohort study. We analyzed the suitability of the biomarkers for the prediction of mortality in a multiple COX regression analysis. We considered as confounder: Age, sex, numerous confounders for COPD, cardiovascular risk factors, and manifest cardiovascular diseases.
Results: Plasma samples were measured of more than thousand patients with stable COPD (GOLD 0-4, GOLD A-D) from the German COPD cohort study COSYCONET.
In Cox regression analyses including adjustments for COPD assessments, cardiovascular risk factors and cardiovascular diseases proadrenomedullin and copeptin predict significantly all-cause mortality in contrast to fibrinogen. The ROC analysis showed a more favorable AUC for the biomarkers adrenomedullin (AUC 0.664) and copeptin (0.632) compared to fibrinogen (0.537). The combination of quality of life scores CAT and MRC did not result in a marked increase in sensitivity and specificity.
Conclusions: Proadrenomedullin and copeptin are better predictors for all-cause mortality in stable COPD than fibrinogen.
Footnotes
Cite this article as Eur Respir J 2022; 60: Suppl. 66, 4292.
This article was presented at the 2022 ERS International Congress, in session “-”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2022
